Search

Your search keyword '"Janus, Cecile"' showing total 14 results
Start Over Author "Janus, Cecile" Publication Year Range Last 3 years
14 results on '"Janus, Cecile"'

2. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, primary, Krul, Inge M., additional, Schaapveld, Michael, additional, Janus, Cecile P. M., additional, Rademakers, Saskia E., additional, Roesink, Judith M., additional, Nijziel, Marten R., additional, Bilgin, Yavuz M., additional, Aleman, Berthe M. P., additional, and van Leeuwen, Flora E., additional

Published
2023
Full Text
View/download PDF

3. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

6. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

7. Risk of male breast cancer after Hodgkin lymphoma

Author

van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Published
2023
Full Text
View/download PDF

8. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., Lansdorp-Vogelaar, Iris, Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 mg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 mg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 mg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 mg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was

Published
2022

9. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Abstract

Background: Hodgkin’s lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously. An average-risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high-grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average-risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow-up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors.

Published
2022

10. Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and/or infradiaphragmatic radiotherapy

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, Lansdorp-Vogelaar, Iris, MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, and Lansdorp-Vogelaar, Iris

Published
2022

11. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Published
2022

12. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.

Author

Ykema, Berbel L. M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H. M., Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Aleman, Berthe M. P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 µg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 µg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 µg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 µg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was the most cost-effective strategy. Impact: Colorectal cancer surveillance should be implemented in Hodgkin lymphoma survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin's lymphoma survivors.

Author

Ykema, Berbel L. M., Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., Aleman, Berthe M. P., Dekker, Evelien, Verbeek, Wieke H. M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, and Snaebjornsson, Petur

Subjects
HODGKIN'S disease, ADENOMATOUS polyps, TUMORS, LOGISTIC regression analysis, CLINICAL pathology, DNA mismatch repair, BREAST cancer prognosis, PROGRESSION-free survival
Abstract

Background: Hodgkin's lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right‐sided, were detected, as published previously. An average‐risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high‐grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average‐risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow‐up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Risk of male breast cancer after Hodgkin lymphoma

Author

de Vries, Simone, Krul, Inge M., Schaapveld, Michael, Janus, Cecile P. M., Rademakers, Saskia E., Roesink, Judith M., Nijziel, Marten R., Bilgin, Yavuz M., van Leeuwen, F. E., Nijdam, A., Aleman, B. M. P., de Boer, J. P., Janus, C. P. M., Mutsaers, P. G. N. J., So-Osman, C., Zijlstra, J. M., Meijer, O. W. M., Rademakers, S. E., Krol, A. D. G., Kersten, M. J., Tonino, S. H., Jalink, M., Daniëls, L. A., van Spronsen, D. J., van der Maazen, R. W. M., Loonen, J., Roesink, J. M., Oostvogels, R., de Weijer, R., Buter, D., de Boer, A., Aarsman, K. M., Oudbier, C. W., Nijziel, M. R., van den Berg, M., Verschueren, K., Schippers, M., Boersma, R. S., Issa, D. E., Plattel, W. J., Stedema, F. G., Koene, H. R., Raymakers, E. R. P. M., Schimmel, E., van Hezewijk, M., Bouma, P., Muller, K., Siemes, C., van der Spek, J. M., Ong, F., Jonkman, A., de Jongh, E., Sprangers, S., Kortleve, J. P., Vermeiden, C. M., Ta, B., Vercoulen, L., Paulissen, J., Posthuma, E. F. M., Brouwer, R. E., Soechit, S., van der Wiel, M., Böhmer, L., Bilgin, M. Y., Kuipers, S., Houmes, M., te Boome, L., Gommers, S., Aleman, Berthe M. P., and van Leeuwen, Flora E.

Abstract

•Male survivors of HL treated with chest radiotherapy have an increased risk of developing BC compared with the general population.•Although the occurrence of male BC is an uncommon event, clinicians should be alert to BC symptoms in male survivors of HL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results